Download PDF
Klin Monbl Augenheilkd 2003; 220(6): 391-395
DOI: 10.1055/s-2003-40273
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Nebenwirkungen des Virustatikums Cidofovir am Auge

Ocular Complications of the Virostatic Drug CidofovirUwe  Hackethal1 , Christian  Holzapfel2 , Heinrich  Gerding1 , Ingo  W.  Husstedt3
  • 1Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Münster
  • 2Klinik und Poliklinik für Psychosomatik und Psychotherapie, Universitätsklinikum Münster
  • 3Klinik und Poliklinik für Neurologie, Universitätsklinikum Münster
Further Information

Publication History

Eingegangen: 12. Dezember 2002

Angenommen: 9. Mai 2003

Publication Date:
27 June 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Cidofovir ist ein Virustatikum aus der Gruppe der Nukleotidanaloga mit Wirksamkeit gegen Herpesviren. Hauptindikation ist derzeit die Behandlung der CMV-Retinitis. Neuere Untersuchungen belegen eine zusätzliche Wirksamkeit von Cidofovir bei durch JC-Virus-Reaktivierung verursachter progressiver multifokaler Leukoenzephalopathie (PML). Schwerwiegendste okuläre Komplikation bei Verabreichung von Cidofovir stellt die chronische, therapieresistente Hypotonia bulbi dar, welche durch sekundäre Komplikationen (Makulafalten, Netzhaut-/Aderhautablösung) zu ausgeprägter, permanenter Visusminderung führen kann. Die Entstehung der Drucksenkung ist nicht endgültig geklärt. Eine Behandlung derselben ist nur in Einzelfällen beschrieben worden und in der Effizienz nicht ausreichend gesichert. Als einzig sichere Option bei Auftreten einer Hypotonie verbleibt der Therapiewechsel von Cidofovir auf alternative Substanzen. Zur frühzeitigen Erkennung ophthalmologischer Komplikationen bei Cidofovirtherapie ist eine regelmäßige Kontrolle durch den Augenarzt notwendig.

Abstract

Cidofovir, a nucleotid analogue virostatic drug is effective in the treatment of herpes virus infections. However, cytomegaly infection is the prime indication due to its adverse effects. There is growing evidence suggesting cidofovir's effectiveness against progressive multifocal leukoencephalopathy (PML) caused by a reactivation of JC-virus. Chronic ocular hypotension which seems to be therapy refractory and anterior uveitis are considered to be the most serious ocular complications of cidofovir. Secondary side effects such as macular folds, retinal or choroidal detachment can result in a permanent loss of vision. Little is known about the pathology of reduced intraocular pressure and only few reports deal with therapeutical attempts to compensate this complication. Abandoning cidofovir presently remains the only therapeutic option. To avoid serious damage it is of utmost importance to monitor all patients undergoing cidofovir administration for signs of anterior uveitis and ocular hypotension.

Schlüsselwörter

Cidofovir - Hypotonia bulbi - Uveitis anterior - progressive multifokale Leukoenzephalopathie (PML) - CMV-Retinitis

Key words

Cidofovir - ocular hypotension - anterior uveitis - progressive multifocal leukoencephalopathy (PML) - cytomegalovirus retinitis

Literatur

  • 1 Accorinti M, Ciapparoni V, Pirraglia M P, Pivetti-Pezzi P. Treatment of severe ocular hypotony in AIDS patients with cytomegalovirus retinitis and cidofovir-associated uveitis.  Ocul Immunol Inflamm. 2001;  9 (3) 211-217
    PubMedGoogle Scholar
  • 2 Akler M E, Johnson D W, Burman W J, Johnson S C. Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis.  Ophthalmology. 1998;  105 (4) 651-657
    CrossrefPubMedGoogle Scholar
  • 3 Ambati J, Wynne K B, Angerame M C, Robinson M R. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis.  Br J Ophthalmol. 1999;  83 (10) 1153-1158
    PubMedGoogle Scholar
  • 4 Bainbridge J W, Raina J, Shah S M, Ainsworth J, Pinching A J. Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS.  Eye. 1999;  13 (Pt 3a) 353-356
    PubMedGoogle Scholar
  • 5 Banker A S. et al . Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis.  Am J Ophthalmol. 1997;  124 (2) 168-180
    PubMedGoogle Scholar
  • 6 Berger J R. Progressive multifocal leukoencephalopathy.  Curr Treatm Opt Neurol. 2000;  2 (4) 361-368
    PubMedGoogle Scholar
  • 7 Bienz K A. Erreger viraler Infektionskrankheiten. In: Kayser FH (Hrsg) Medizinische Mikrobiologie. Stuttgart; Thieme 1993: 342-344
    Google Scholar
  • 8 Cardenas R L, Chen K H, Sack K. The effects of cidofovir on progressive multifocal leukoencephalopathy: an MRI case study.  Neuroradiology. 2001;  43 (5) 379-382
    CrossrefPubMedGoogle Scholar
  • 9 Chavez de la Paz E. et al . Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention.  Ophthalmology. 1997;  104 (7) 539-544
    PubMedGoogle Scholar
  • 10 Cochereau I. et al . Uveitis in patients treated with intravenous cidofovir.  Ocul Immunol Inflamm. 1999;  7 (3 - 4) 229-233
    PubMedGoogle Scholar
  • 11 Conway B, Halliday R C, Brunham R C. Human immunodefiency virus associated progressive multifocal leukoencephalopathy: apparent response to 3'-azido-3'-deoxythymidine.  Rev Infect Dis. 1990;  12 (3) 479-482
    PubMedGoogle Scholar
  • 12 Davis J L, Taskintuna I, Freeman W R, Weinberg D V, Feuer W J, Leonard R E. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis.  Arch Ophthalmol. 1997;  115 (6) 785-786
    PubMedGoogle Scholar
  • 13 De Luca A. et al . Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy.  AIDS. 2000;  29, 14 (14) 117-121
    PubMedGoogle Scholar
  • 14 Garweg J G. Anterior segment involvement in HIV-related eye disease after the commencement of highly active antiretroviral therapy (HAART).  Klin Monatsbl Augenheilkd. 2000;  216 (2) 61-67
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Gasnault J. et al . Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy.  J Neurovirol. 1999;  5 (4) 421-429
    PubMedGoogle Scholar
  • 16 Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP).  Hematol Cell Ther. 1999;  41 183-186
    CrossrefPubMedGoogle Scholar
  • 17 Haider S, Nafziger D, Gutierrez J A, Brar I, Mateo N, Fogle J. Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: a case report and review of reported cases.  Clin Infect Dis. 2000;  31 (4) E20-22
    CrossrefPubMedGoogle Scholar
  • 18 Happe S. et al . Cidofovir (vistide) in therapy of progressive multifocal leukoencephalopathy in AIDS. Review of the literature and report of 2 cases.  Der Nervenarzt. 1999;  70 (10) 935-943
    CrossrefPubMedGoogle Scholar
  • 19 Happe S. et al . Progressive multifokale Leukoenzephalopathie im Verlauf der AIDS-Erkrankung.  Der Nervenarzt. 2000;  71 96-104
    CrossrefPubMedGoogle Scholar
  • 20 Holzapfel C. et al . Progressive multifocal leukoencephalopathy (PML) as an opportunistic infection in chronic lymphatic leukaemia (CLL). Review of the literature and case report.  Der Nervenarzt. 2002;  73 (6) 543-547
    CrossrefPubMedGoogle Scholar
  • 21 Houston S, Roberts N, Mashinter L. Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus.  Clin Infect Dis. 2001;  32 (1) 150-152
    CrossrefPubMedGoogle Scholar
  • 22 Inui K. et al . Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection.  Brain Dev. 1999;  21 (6) 416-419
    CrossrefPubMedGoogle Scholar
  • 23 Jacobson M A, Wilson S, Stanley H, Holtzer C, Cherrington J, Safrin S. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS.  Clin Infect Dis. 1999;  28 (3) 528-533
    PubMedGoogle Scholar
  • 24 Kersten A J, Althaus C, Best J, Sundmacher R. Cystoid macular edema following immune recovery and treatment with cidofovir for cytomegalovirus retinitis.  Graefe's Arch Clin Exp Ophthalmol. 1999;  237 (11) 893-896
    PubMedGoogle Scholar
  • 25 Kirsch L S, Arevalo J F, Chavez de la Paz E, Munguia D, Clerq E de, Freeman W R. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with aquired immune deficiency syndrome.  Ophthalmology. 1995;  102 (4) 533-542
    PubMedGoogle Scholar
  • 26 Labetoulle M, Goujard C, Frau E, Offret H, Delfraissy J F, Gasnault J. Cidofovir ocular toxicity is related to previous ocular history.  AIDS. 2000;  31, 14 (5) 622-623
    PubMedGoogle Scholar
  • 27 Ledergerber B. et al . AIDS-related opportunistic illnesses occuring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.  JAMA. 1999;  282 (23) 2220-2226
    CrossrefPubMedGoogle Scholar
  • 28 Martinez de la Casa J M, Matilla-Rodero M, Castillo A, Garcia Feijoo J, Garcia Sanchez J. Ocular complications after treatment with intravenous cidofovir for cytomegalovirus retinitis.  Arch Soc Esp Oftalmol. 2001;  76 (4) 213-220
    PubMedGoogle Scholar
  • 29 Pharmacia & Upjohn GmbH .Zusammenfassung der Merkmale des Arzneimittels Vistide.  Anforderung: Bundesverband der Pharmazeutischen Industrie e. V., Stand der Information 17. Juni 1999
    Google Scholar
  • 30 Plosker G L, Noble S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.  Drugs. 1999;  58 (2) 325-345
    PubMedGoogle Scholar
  • 31 Portilla J, Boix V, Roman F, Reus S, Merino E. Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active anti-retroviral therapy.  J Infect. 2000;  41 (2) 182-184
    CrossrefPubMedGoogle Scholar
  • 32 Rougier M B. et al . Anterior uveitis and cidofovir.  J Fr Ophtalmol. 2001;  24 (5) 491-495
    PubMedGoogle Scholar
  • 33 Segarra-Newnham M, Vodolo K M. Use of cidofovir in progressive multifocal leukoencephalopathy.  Ann Pharmacother. 2001;  35 (6) 741-744
    CrossrefPubMedGoogle Scholar
  • 34 Tantisiriwat W. et al . Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.  Clin Infect Dis. 1999;  28 (5) 1152-1154
    PubMedGoogle Scholar
  • 35 Taskintuna I. et al . Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrom (AIDS).  Ophthalmology. 1997;  104 (11) 1827-1836
    PubMedGoogle Scholar
  • 36 Taskintuna I. et al . An animal model for cidofovir (HPMPC) toxicity: intraocular pressure and histopathologic effects.  Exp Eye Res. 1997;  64 (5) 795-806
    CrossrefPubMedGoogle Scholar
  • 37 Tseng A L, Mortimer C B, Salit I E. Iritis associated with intravenous cidofovir.  Ann Pharmacother. 1999;  33 (2) 167-171
    PubMedGoogle Scholar

Dr. U. Hackethal

Klinik und Poliklinik für Augenheilkunde Universitätsklinikum Münster

Domagkstraße 15

48149 Münster

Phone: + 49/251/835-6001

Fax: + 49/251/835-6003

Email: hacketu@mednet.uni-muenster.de

      >